arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Pasithea Therapeutics Corp.

KTTA
$0.51 ▲ +0.06 (+12.36%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Pasithea Therapeutics Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $12.4M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -7.0%
FCF / Share $-0.20
Trailing P/E
Price / Book 0.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$218.61K
↑ +1509.7%
Net Income Profit after all expenses
$-2.87M
↑ +19.5%
FCF / Share Free cash flow per share
$-0.20
↑ +85.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
20
Financial Health
3
Cash Quality
50

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 23 quarters